COMMONLY ASKED QUESTIONS

The number of arthroplasties being performed increases each year. Patients undergoing an arthroplasty are at risk of venous thromboembolism (VTE) and appropriate prophylaxis has been recommended. However, the optimal protocol and the best agent to minimise VTE under these circumstances are not known. Although many agents may be used, there is a difference in their efficacy and the risk of bleeding. Thus, the selection of a particular agent relies on the balance between the desire to minimise VTE and the attempt to reduce the risk of bleeding, with its undesirable and occasionally fatal, consequences.

Acetylsalicylic acid (aspirin) is an agent for VTE prophylaxis following arthroplasty. Many studies have shown its efficacy in minimising VTE under these circumstances. It is inexpensive and well-tolerated, and its use does not require routine blood tests. It is also a ‘milder’ agent and unlikely to result in haematoma formation, which may increase both the risk of infection and the need for further surgery. Aspirin is also unlikely to result in persistent wound drainage, which has been shown to be associated with the use of agents such as low-molecular-weight heparin (LMWH) and other more aggressive agents.

The main objective of this review was to summarise the current evidence relating to the efficacy of aspirin as a VTE prophylaxis following arthroplasty, and to address some of the common questions about its use.

There is convincing evidence that, taking all factors into account, aspirin is an effective, inexpensive, and safe form of VTE following arthroplasty in patients without a major risk factor for VTE, such as previous VTE.

Cite this article: Bone Joint J 2017;99-B:1420–30.

The number of arthroplasties increases each year.1 Patients undergoing an arthroplasty are at risk of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE).2 In the absence of prophylaxis, VTE may occur in more than 35% of patients undergoing an arthroplasty. However, most are asymptomatic.2–6 Because of the relatively high incidence of VTE, prophylaxis has been recommended after arthroplasty.7 The best agents and optimum protocols to minimise VTE under these circumstances are not known. The most recently revised guidelines from the American College of Chest Physicians (ACCP) and associated guidance from the American Academy of Orthopaedic Surgeons (AAOS) offer valuable recommendations. Both accept mechanical and chemical prophylaxis.2,8 Although there are many chemical agents for VTE prophylaxis, there is a difference in their efficacy and the risk of bleeding. The choice of agent therefore relies on a balance between the desire to minimise VTE and the attempt to reduce the risk of bleeding, with its undesirable and occasionally fatal consequences.9–14

Acetylsalicylic acid, which is generally known as aspirin, is an agent for the prevention of VTE following arthroplasty.9,10,15–21 Many studies have reported its efficacy in minimising VTE following arthroplasty.9,10,15–36 In recent years, there has been a dramatic shift, at least in North America, towards the use of aspirin as the main modality for VTE prophylaxis following arthroplasty.9,12,16,20,27,37–43 A recent poll of >1200 attendees of the annual meeting of the American Association of Hip and Knee Surgeons, in 2016, revealed that >80% use aspirin as the main prophylaxis in their patients undergoing arthroplasty of the hip or knee.

There are various reasons for the popularity of aspirin as a prophylactic agent. Besides the proven efficacy, it is inexpensive and well-tolerated, and its use does not require routine blood monitoring.4,7,12,18,21,23,24,44,45 It is also a ‘milder’ agent that is unlikely to result in haematoma formation, which may require further surgery, and which increases the risk of
infection.27 Aspirin is also less likely to be associated with persistent wound drainage, with all its undesirable consequences, than agents such as low-molecular-weight heparin (LMWH) or other more aggressive agents.4,14,23,46,51

There are other reasons why there has been a recent increasing use of aspirin as VTE prophylaxis in North America. One may relate to the advances in anaesthesia and surgical techniques that have changed the nature of arthroplasty.

The use of regional anaesthesia, multimodal pain management with less reliance on opioids, and the effective conservation of blood allows most patients to walk within hours of their surgery, unlike in the recent past, when patients would be unable to walk for several days after the operation. Many centres around the world now undertake arthroplasty as an outpatient procedure.26,52-59 The increasing use of pre-operative training and exercise classes allows faster mobilisation after surgery.60,61 The fact that an arthroplasty is a more routine and predictable procedure means that patients present earlier for surgery and are therefore more mobile pre-operatively. The reduction in waiting lists for surgery in some countries has also probably improved the pre-operative fitness of patients and thus facilitated their post-operative mobilisation.62 Another reason for the move towards aspirin may relate to the economics of arthroplasty. For reasons of cost containment, healthcare providers may have to bear the costs of complications and re-admissions, which encourages strategies that minimise wound-related problems that may require treatment, including further surgery.63,64 The association between haematoma formation, persistent wound drainage and periprosthetic infection has also sensitised the orthopaedic community towards the use of less aggressive VTE prophylaxes, such as aspirin, that minimise the risk of these complications.27,47,50,65,66 There is also an increasing concern about infection with multiply resistant organisms, which are difficult to manage.67,68 This problem means that the balance of risk and cost is now relatively more in favour of techniques that reduce infection.

Despite the popularity of aspirin in the United States, some European countries have refrained from adopting aspirin as VTE prophylaxis following arthroplasty. Some European guidelines, such as the Scottish Intercollegiate Guidelines Network (SIGN) and the National Institute for Health and Care Excellence (NICE), dispute its efficacy.69,70 The committees that guide the formation of guidelines may receive evidence from experts in haematology, internal medicine and other subspecialties, who question the efficacy of aspirin as an antithrombotic agent. These committees work with controlled trial data and ignore registry data, which provide the evidence of the outcomes of orthopaedic procedures.

The main objective of this review is to summarise the current evidence relating to the efficacy of aspirin as VTE prophylaxis following arthroplasty, and to address some of the common questions that are asked by orthopaedic surgeons and other interested colleagues.

What is the mode of action of aspirin?

Aspirin is an extensively studied antithrombotic agent that irreversibly inhibits the activity of cyclooxygenase (COX) in platelets,71-74 COX-1 and 2 isoenzymes catalyse the conversion of arachidonic acid to prostaglandin (PG) H2 and the production of thromboxane A2 (TXA2) and PGI2. TXA2 induces vasoconstriction, whereas PGI2 induces vasodilatation and inhibits the aggregation of platelets.75 Aspirin exerts its activity by inhibiting COX-1, which in turn inhibits the production of TXA2. Aspirin can prevent the subendothelial deposition of platelets and the aggregation of new platelets.76-78

The Virchow triad, consisting of a combination of endothelial damage, venous stasis and hypercoagulability, can trigger the development of thrombosis.79 All three components are relevant in lower limb arthroplasty. The development of a venous thrombus often starts in the region of a valve where the pattern of blood flow becomes abnormal, resulting in endothelial dysfunction.72,79 Stagnant blood in a linear section of the blood vessel leads to hypoxia,80 which in turn initiates thrombogenesis and the aggregation of platelets.75

Is aspirin effective in the prevention of VTE following arthroplasty and other orthopaedic procedures?

To our knowledge, a study by Salzman et al81 is the first report in the English literature that demonstrated the efficacy of aspirin in reducing VTE after total hip arthroplasty (THA). There have been many subsequent studies further showing the efficacy and safety of aspirin for VTE prophylaxis following arthroplasty.9,10,14-16,18-23,27,30,32,33,39,41,44,46,51,81-97

One of the most important and commonly cited studies is the Pulmonary Embolism Prevention (PEP) Trial.15 This multinational and prospective study, involving more than 24 000 patients, confirmed the efficacy of aspirin in the prevention of VTE for patients undergoing arthroplasty and for those with a fracture of the hip.13 The use of aspirin reduced the incidence of PE and DVT post-operatively by at least a third. The study concluded that “there is now good evidence for considering aspirin routinely in a wide range of surgical and medical groups at high risk of VTE”.15 The publication of many further studies showing the same thing resulted in the ACCP endorsing aspirin with the highest grade of recommendation, and for the AAOS to accept aspirin as prophylaxis for patients undergoing arthroplasty.13,18,19,22,23,25,29,31,34,65,98,99

Does aspirin work on the venous circulation (black clot) or is its action limited to the arterial circulation (red clot)?

The action of aspirin is not limited to the arterial circulation. As mentioned above, it inhibits platelet aggregation,75 an important instigator of venous thrombosis.76,78,100 Besides COX-1 inhibition, several mechanisms of action have been proposed for the antithrombotic effects of
aspirin in VTE prophylaxis. It suppresses the activation and aggregation of platelets via non-cyclooxygenase-1 pathways. It also attenuates the generation of thrombin by the acetylation of antithrombin III and prothrombin, decreasing tissue factor expression on monocytes and macrophages and impairing the formation of prothrombinase on platelets with reduced activation of factor V. Aspirin acetylates fibrinogen and fibrin and inhibits the activation of thrombin-mediated factor XIII, resulting in the formation of looser networks of fibrin with increased lysisability. There is some evidence that platelet activation in association with neutrophil recruitment is involved in the initiation and propagation of a DVT. Neutrophil extracellular traps (NETs) are produced to allow neutrophils to trap and disarm microbes in the extracellular environment. They stimulate the formation and deposition of fibrin which joins NETs in thrombi. NETs stimulate both the extrinsic and intrinsic coagulation pathways. Aspirin may reduce the phosphorylation of nuclear factor kappa B to impair the formation of NETs.

It has been shown that aspirin reduces the risk of recurrent DVTs. The randomised, multicentre, double-blind, placebo-controlled Aspirin for the Prevention of Recurrent Venous Thromboembolism Warfarin and Aspirin (WARFASA) trial showed that in patients with an initial unprovoked VTE (n = 403) who had completed six to 18 months of treatment with vitamin K antagonists and then were assigned to aspirin (100 mg/day) for two years, VTE recurred in 6.6% of those receiving aspirin compared with 11.2% of those receiving a placebo (p = 0.02). Many other studies have further shown the efficacy of aspirin in minimising VTE following arthroplasty, all recording its action on the venous (black clot) circulation.

**Does aspirin prevent all VTEs or just DVTs?**

The efficacy of aspirin in the prevention of VTE includes its ability to reduce the incidence of both proximal and distal DVTs, and non-fatal and fatal PEs. A recent study showed that low dose aspirin (81 mg twice a day) was as effective as a higher dose (325 mg twice a day), with the lower dose being associated with fewer gastrointestinal side effects. The recommendation of that study was that low dose aspirin should be used for the prevention of VTE following arthroplasty.

**How long should aspirin be used for after an arthroplasty?**

The initial AAOS guidelines on the prevention of VTE, published in 2007, recommended that aspirin prophylaxis should continue for six weeks after an arthroplasty. The recent ACCP guidelines, on the other hand, recommended that aspirin prophylaxis should only be continued for ten to 14 days after arthroplasty, with the recommendation having strong evidence (Grade 1B), but also suggesting extended prophylaxis for 30 to 35 days with weak evidence (Grade 2C). Other protocols advocate using aspirin until discharge from hospital, or for seven days, 14 days, 21 days, 28 days, or six weeks. A recent study showed that most symptomatic VTEs (94%) occur within two weeks of an arthroplasty, with 89% occurring within the first week. Based on this study and the recommendations of the ACCP, it is plausible that the administration of aspirin for two weeks following an arthroplasty may usually be sufficient. Since some studies have shown the risk of VTE remains higher than the general population for much longer after an arthroplasty and bearing in mind the low toxicity of aspirin, the use of extended prophylaxis, particularly in high-risk patients who are less mobile, may also be reasonable. In view of the complexity of the data on the length of prophylaxis and variation of a patient’s response to aspirin, further studies examining the duration of prophylaxis using aspirin, or other agents, are needed.

**Does aspirin have any adverse effects?**

It appears that aspirin is safe and causes fewer complications than other chemical agents available for VTE prophylaxis.
Based on our institutional experience and evaluation of the literature, adverse events are rare with the use of aspirin. It can, especially at higher doses, cause dyspepsia, gastroesophageal reflux, and an increased risk of upper gastrointestinal bleeding. Aspirin can induce small and large bowel pathology (enteropathy); this was not well recognised previously. It is not known what percentage of patients develop these adverse effects but gastrointestinal bleeding, if untreated, can be fatal. Patients developing adverse events related to the administration of aspirin, should discontinue its use.

Any prophylaxis given to patients for the prevention of VTE carries potential for unintended effects. Many studies have shown that LMWH increases the risk of minor and major bleeding and wound-related complications. Bloch et al recorded that dabigatran caused a significant increase in leakage from the wound (p < 0.001), an increase in the length of stay in hospital (p = 0.04) and higher rates of VTE (p = 0.047) when compared with the use of a multimodal prophylaxis protocol (LMWH inpatient and extended use of aspirin). Zou et al compared oral rivaroxaban, LMWH and aspirin to prevent VTE in patients undergoing total knee arthroplasty (TKA). They found that rivaroxaban caused significantly greater hidden blood loss and more wound complications compared with LWMH and aspirin. It is also believed that warfarin, because of its ability to inhibit proteins C and S, both of which have anticoagulant properties, can result in a temporary hypercoagulable state in the immediate post-operative period. In a study by Raphael et al patients receiving warfarin for VTE prophylaxis after arthroplasty had a six times higher incidence of PE compared with those receiving aspirin.

**Does aspirin have any unintended beneficial effects?**

The administration of aspirin as VTE prophylaxis may also carry some unintended beneficial events. It has recently been shown that the incidence of mortality after arthroplasty is lower in patients using aspirin than in those using warfarin. LMWH, ximelagatran, fondaparinux, or rivaroxaban. Hunt et al showed that mechanical and chemical thromboprophylaxis with heparin with or without aspirin were associated with a decreased 90-day mortality in 409 096 patients undergoing primary THA. They also reported that the 45-day mortality with aspirin after TKA was slightly lower than the mortality with heparin, although this did not reach statistical significance. The latter is not surprising as myocardial infarction and not PE is the main cause of mortality following arthroplasty. PE is responsible for between 11.7% and 17.1% of 90-day mortality, while a myocardial infarction is responsible for 25.9%. The true cause of death in many patients who do not have an autopsy remains unknown. It is likely that some cases recorded as PE occur as a result of cement or marrow embolisation and are not a true VTE. The incidence of cardiac events leading to death following arthroplasty may be underestimated. In a study by Blom et al, ischaemic heart disease was found to be responsible for 41.2% of deaths after THA.

The anti-platelet effects of aspirin are well-established for the secondary prevention of cardiovascular disease. Aspirin also reduces cardiac-related peri-operative mortality. Although this unintended benefit of aspirin in patients undergoing an arthroplasty has received little attention, one notable study by Parry et al reported that death from all cardiovascular causes decreased from 0.75% (13 of 1727 patients) to zero after switching from no prophylaxis to that involving 75 mg aspirin after THA. The beneficial effect of aspirin relates to its ability to prevent arterial thrombosis that is the cause of myocardial infarction and stroke. It has been shown that major non-cardiac operations are also associated with a temporarily increased risk of arterial thrombosis, encompassing myocardial infarction and stroke.

A study based on the Danish national registry, which included patients undergoing a primary THA or TKA (n = 95 227), who were matched to controls, showed that the incidence of myocardial infarction was significantly increased in the first two weeks after THA (adjusted hazard ratio (HR), 25.5; 95% CI, 17.1 to 37.9) and TKA (adjusted HR, 30.9; 95% CI, 11.1 to 85.5) compared with controls.

THA or TKA may be complicated by a stroke. Mortazavi et al reported that the incidence of stroke following arthroplasty was 0.2% (36 of 18 745). Of the 36 strokes, two were haemorrhagic and 34 were ischaemic. They found that 25% of patients developing a stroke died within the first post-operative year. Although it is rare following arthroplasty, the consequences of a stroke can be devastating, particularly in elderly patients. A recent systematic review found that aspirin was superior to other anticoagulants in the prevention of arterial thrombosis after THA and TKA. Future studies with larger samples may better delineate the role of aspirin in preventing stroke after arthroplasty.

Aspirin may have another beneficial effect, in that it may reduce the incidence of heterotopic ossification following THA. The anti-inflammatory effect of aspirin may also contribute to better control of pain and the decreased use of opioids.

**Is aspirin cost-effective?**

Aspirin is inexpensive and reduces the direct and indirect costs associated with VTE prophylaxis. Gutowski at al reported that the use of aspirin compared with warfarin following arthroplasty reduced the costs related to VTE by shortening the length of hospital stay and lowering the incidence of PE and of all complications related to VTE prophylaxis (p < 0.001 for all). They did not take into account the cost of monitoring treatment with warfarin, which is time-consuming, invasive, and expensive. Many other studies have shown that the use of aspirin after arthroplasty results in a shorter hospital stay than...
when using other agents. There are various reasons for this finding. The use of aspirin does not require blood tests (like warfarin) that can delay discharge from hospital until target therapeutic levels are obtained. Aspirin has anti-inflammatory properties that may aid rehabilitation and the return of function. Keas et al compared the effect of aspirin and LMWH on the early return of movement of the knee after TKA and found that movement returned faster in the aspirin group (p < 0.001). The early return in function reduces the incidence of complications and the costs associated with rehabilitation. An early discharge from hospital for patients on aspirin may relate to the lower incidence of wound-related complications and of further surgery.

The cost-effectiveness of aspirin versus other agents has also been studied. Jameson et al reported that the annual cost of VTE prophylaxis with potent anticoagulants in patients undergoing arthroplasty in the United Kingdom and Wales was about £13 million, compared with about £110 000 if aspirin was used. Schousboe et al compared aspirin and LMWH and showed that, using quality-adjusted life-years (QALYs), the use of aspirin was cost-effective for patients with no history of VTE after THA and for those who are aged > 80 years after TKA. They were uncertain about the most cost-effective method of VTE prophylaxis for those undergoing TKA who are aged < 80 years. A recent cost-effectiveness analysis, comparing the use of aspirin and warfarin after arthroplasty, clearly showed that aspirin was cost-effective and saved more QALYs than warfarin in all age groups. The realistic costs of administering potent anticoagulants are even higher when one takes into account the increased rate of wound-related problems, haematoma formation, and subsequent deep infection.

Can aspirin be administered with other nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-II inhibitors?

NSAIDs and aspirin are often prescribed together to address pain and for VTE prophylaxis after arthroplasty. NSAIDs can be conventional non-selective agents, or COX-II selective or COX-IV selective. The antiplatelet effect of aspirin is almost entirely COX-I dependent. Conventional non-selective NSAIDs and aspirin inhibit the same COX enzymes, and therefore may interact. Meek et al investigated the interaction between aspirin and selective different (meloxicam and etoricoxib) and non-selective (ibuprofen and naproxen) NSAIDs on thrombocytic function. Meloxicam and etoricoxib caused no significant change in aspirin’s thrombocytic inhibition, which, in contrast, was prevented by ibuprofen and naproxen. Aspirin cannot bind to COX-I if the binding site is already occupied by a NSAID. The effect of this is that the administration of non-selective NSAIDs a few hours before aspirin may impede the antithrombocytic effect. When NSAIDs bind to COX-I, it is reversible. Hence, the timing of the administration of the non-selective NSAID and aspirin should be taken into consideration regarding the time interval for their potential for interaction. Ibuprofen and naproxen reduce the antithrombocytic effect of aspirin when single dosages of NSAID are administered two hours before aspirin, but not if the same NSAID is used two hours after aspirin. On the other hand, many studies have shown that aspirin can be administered with selective COX-II inhibitors (celecoxib) and COX-III inhibitors (paracetamol) without interfering with its antithrombocytic effect.

Is there a difference between the efficacy, adverse events, and cost of the enteric- and non-enteric-coated formulations?

Aspirin is associated with gastrointestinal symptoms, which can result in damage to the gastric mucosa by the suppression of the mucosal synthesis of prostaglandin and its topical irritant effects on the epithelium. Aspirin thus reduces mucosal defences, including epithelial cell turnover and repair, blood flow, and the secretion of mucus and bicarbonate. Enteric-coated aspirin is covered with a combination of cellulose, silicon and other inactive ingredients. This allows it to dissolve in the duodenum rather than the stomach. Several authors have reported that enteric-coated aspirin causes significantly less mucosal damage than uncoated aspirin, with others refuting this claim. With the conflicting reports in the literature, it is not currently known whether enteric-coated aspirin is superior to non-enteric-coated aspirin with regard to VTE prophylaxis or the incidence of adverse effects. A recent study showed that the rate of gastrointestinal upset and nausea in patients receiving 325 mg of aspirin was higher (9 of 282, 3.2%) than those who received 81 mg (3 of 361, 0.8%; p = 0.04). However, gastrointestinal bleeding was 0.7% in the 325 mg group and 1.1% in the 81 mg group (p = 0.70). According to the British National Formulary, the cost of 28 aspirin (75 mg) tablets is 84 pence and the cost for the same number of enteric-coated tablets is 87 pence.

Is the use of aspirin for the prevention of VTE accepted by any regulatory body or guidelines?

The fourth and eighth editions of the ACCP evidence-based clinical practice guidelines, published in 2004 and 2008, respectively, recommended against the use of aspirin for VTE prophylaxis in patients undergoing arthroplasty. The guidelines were based mainly on studies that assessed the efficacy of agents for the prevention of mostly asymptomatic distal DVT rather than PE. Little evidence about the efficacy of chemical prophylaxis in reducing all-cause mortality was available. There are few studies that deal with the use of aspirin for the prevention of early post-operative DVT. Studies evaluating the incidence of DVT, including asymptomatic DVT, in the early post-operative period use DVT as a surrogate endpoint for PE. These studies are mostly conducted by pharmaceutical companies in their...
effort to gain regulatory approval for the agents. The previous guidelines have raised concerns among orthopaedic surgeons, particularly because they did not consider all-cause mortality and there was a need to establish a balance between VTE prophylaxis and post-operative bleeding.

The ACCP guidelines were extensively quoted in the United Kingdom in a House of Commons Health Select Committee report on VTE. The Committee also took evidence from organisations such as charities and individuals who were not required to declare their interests. After guidance was produced by NICE, which recommended chemical prophylaxis using LMWHs rather than aspirin, an all-party Parliamentary Thrombosis Group was established to raise awareness of the issue by writing to hospital trusts on parliamentary notepaper. The parliamentary group was supported by a consultancy group that was partly funded by pharmaceutical companies. Recently, the workings of this type of group have been considerably tightened by the Parliamentary Standards Commissioner to prevent the misuse of Parliamentary logos and insignias.

In 2007, the AAOS issued a guideline focused on the prevention of symptomatic rather than asymptomatic VTE. This recommended aspirin 325 mg twice daily for six weeks for patients at standard risk of PE and major bleeding, those with a standard risk of PE and elevated risk of major bleeding, and those with an elevated risk of PE and major bleeding groups separately.

In the United Kingdom, NICE produced guidelines in 2010 that were similar to the eighth edition of the ACCP guidelines. These recommended against the use of aspirin for VTE prophylaxis. Other important orthopaedic organisations in the United Kingdom, such as the British Hip Society, accept the use of aspirin for VTE prophylaxis. Despite the NICE guidelines, some surgeons in the United Kingdom continue to use aspirin, with many centres reporting their encouraging experience. In a similar way to the change in the ACCP guidelines, it may be that NICE will change its evidence base and endpoints for the evaluation of the efficacy of aspirin used in this way.

The ninth edition of the ACCP guidelines, published in 2012, used different endpoints for the prevention of all VTEs, the risk for serious bleeding and mortality related to VTE and antithrombotic therapy. These strongly recommend (Grade 1B) the use of aspirin as an agent for VTE prophylaxis. The inclusion of experts with relevant financial conflicts in the previous panels of the ACCP committee had been criticised. Following this, the committee of the ninth edition made a major change and only approved members with minimal to no financial conflict of interest. Of the 150 initial candidates, 13 were rejected because of a conflict of interest and 18 were included with an agreement for active management of their conflict of interest that removed their right to give an opinion on the final recommendations.

The Health and Medicine Division (HMD) of the National Academies of Sciences, Engineering, and Medicine (the Academies) in the United States applies a meticulous research process, aimed at providing straightforward objective answers to difficult questions of national importance. The HMD was previously the Institute of Medicine (IOM), which produced eight standards for developing rigorous, trustworthy clinical practice guidelines (CPG). The CPGs of the AAOS meet all the IOM standards. The AAOS addresses bias beginning with the selection of CPG group members. Applicants with financial conflicts of interest related to the CPG topic cannot participate if the conflict occurred within one year of the start date of the CPG’s development or if an immediate family member has, or has had, a financial conflict. Additionally, all CPG development group members sign a form agreeing to remain free of financial conflicts for one year following the publication of the CPG.

NICE also has a requirement that members of guideline committees declare their interests. Colleges and professional organisations may be asked to nominate individuals to give evidence to public bodies but they may not have a formal process for taking declarations of interest from the individual. The guidelines for witnesses to Parliamentary committees do not include a requirement to declare interests. Committees have the power to require evidence to be given under oath, but this is rarely used. Witnesses to committees enjoy absolute privilege in respect of the evidence that they give, enshrined in Article 9 of the Bill of Rights 1689. They are thus immune from both civil and criminal proceedings arising from the evidence that they give.

Should aspirin be given to all patients undergoing an arthroplasty as VTE prophylaxis?

The risk for VTE following an arthroplasty is not the same for all patients. Many risk factors for VTE have been identified. A few recent studies, including one from the United Kingdom, recommended that VTE prophylaxis following arthroplasty should be individualised, based on the risk factors. A few studies in the United States have also evaluated the impact of various risk factors on the incidence of VTE following arthroplasty and developed an algorithmic approach. A recent study using the National Inpatient Sample data identified 721,806 patients undergoing arthroplasty, among whom 17,775 (0.9%) developed VTE post-operatively. All known risk factors for VTE were assessed. Relative weights of all independent predictors of VTE after arthroplasty were determined. Hypercoagulability, metastatic cancer, stroke, sepsis, and chronic obstructive pulmonary disease had some of the highest scores. Patients with any of these conditions had a risk of post-operative VTE of > 3%. The authors used this model, and developed an iOS (iPhone operating system, Apple, Inc., Cupertino, California) application (VTEstimator, MedApp LLC, Wilmington, Delaware) that could be used to assign patients into low or high risk for VTE after arthroplasty. Thus, although aspirin is an effective agent for VTE prophylaxis, the use of more potent agents such as LMWH, newly intro-
duced oral agents or warfarin should be considered in patients at a much higher risk in whom the added risk of bleeding with the use of potent agents may be justified. It is possible that individual risk assessment can be improved by the use of tests such as rotational thromboelastometry, which may be used either either-operatively or potentially during surgery to assess individual patients.\(^{184}\) Further studies would be needed, but this technique might identify some high risk patients in whom LMWH should be used, other medium risk patients who should be treated with aspirin and some low risk patients who do not need prophylaxis. Although there is currently no evidence that genetic testing for Factor V Leiden risk patients who do not need prophylaxis. Although there is evidence that genetic testing for Factor V Leiden and genetic variants of prothrombin is beneficial,\(^{185}\) the future development of genetic testing remains a possibility.

Taking all factors into account, there is convincing evidence that aspirin is one of the most effective, inexpensive and safest methods for VTE prophylaxis following arthroplasty, including those with a fracture of the hip. The use of aspirin is associated with a much lower incidence of complications and carries additional benefits, such as a reduction in the incidence of myocardial infarction. Although the optimal dose and length of prophylaxis remains unknown, the evidence is that low dose aspirin (between 70 mg and 100 mg twice a day) for a few weeks may be sufficient for most patients. VTE prophylaxis following arthroplasty should be individualised, perhaps using decision-making tools such as algorithmic-based iOS apps. Further research is required into the role of thromboelastometry and the measurement of the response to treatment using low-dose aspirin. The use of more potent agents, such as the newly introduced oral agents and LMWH, which are associated with a higher incidence of bleeding and wound-related complications, may be justified in patients at higher risk of VTE.

### Take home message:

- The main objective of this review was to summarise the current evidence relating to the efficacy of aspirin as a VTE prophylaxis following total joint arthroplasty, and to address some of the common questions about its use that are asked by orthopaedic surgeons and other interested colleagues.
- There is convincing evidence that, taking all factors into account, aspirin is an effective, inexpensive, and safe form of VTE prophylaxis following total joint arthroplasty in patients without a major risk factor for VTE, such as previous VTE.

### Author contributions:

I. Azboy: Writing the paper.
A. Thomas: Writing the paper.
F. S. Haddad: Writing the paper.
R. Barrack: Writing the paper.
J. Parvizi: Writing the paper.

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

This is an open-access article distributed under the terms of the Creative Commons Attribution license (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.

This article was primary edited by J. Scott.

### References

1. Kurtz SM, Mowat F, Ong K, et al. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg [Am] 2005;87-A:1487–1497.
2. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):2795–2855.
3. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):3385–400S.
4. Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery; a pooled analysis of randomized controlled trials. J Arthroplasty 2009;24(8 Suppl):77–83.
5. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381–453.
6. Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement: an analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg [Am] 1984;66-A:194–201.
7. Markel DC, York S, Liston MJ, et al. Venous thromboembolism management: by American Association of Hip and Knee Surgeons. J Arthroplasty 2010;25:3–9.
8. Johanson NA, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Arthroplasty 2009;17:183–196.
9. Huang RC, Parvizi J, Hozack WJ, Chen AF, Austin MS. Aspirin is as effective as and safer than warfarin for patients at higher risk of venous thromboembolism undergoing total joint arthroplasty. J Arthroplasty 2016;31(9 Suppl):83–86.
10. Lachiewicz PF, Soileau ES. Multimodal prophylaxis for THA with mechanical compression. Clin Orthop Relat Res 2006;453:225–230.
11. Lanaas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, anti-platelet agents, or anti-coagulants. Clin Gastroenterol Hepatol 2010;12:996–99612.
12. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg [Am] 2013;95-A:1801–1811.
13. Parry M, Wylde V, Blom AW. Ninety-day mortality after elective total hip replacement: 1549 patients using aspirin as a thromboprophylactic agent. J Bone Joint Surg [Br] 2008;90-B:306–307.
14. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anti-coagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2009;467:714–721.
15. No authors listed. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295–1302.
16. Deirmengian GK, Heller S, Smith EB, et al. Aspirin can be used as prophylaxis for prevention of venous thromboembolism after revision hip and knee arthroplasty. J Arthroplasty 2016;31(2 Suppl):221–2240.
17. Jiang Y, Du H, Liu J, Zhou Y. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J (Engl) 2014;127:2201–2205.
18. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. J Arthroplasty 2006;452:175–180.
19. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res 1996;324:251–258.
20. Raphael IJ, Tischler EH, Huang R, et al. Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty? Clin Orthop Relat Res 2014;472:482–488.
21. Vulcano E, Gesell M, Esposito A, et al. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop 2012;36:1995–2002.
22. Beksaq B, Gonzalez Della Valle A, Anderson J. Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol. Clin Orthop Relat Res 2007;463:114–119.
23. Bozic KJ, Vail TP, Pekow PS. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010;25:1053–1059.
24. Daniel J, Pradhan A, Predhan C, et al. Multimodal thromboprophylaxis following primary hip arthroplasty: the role of adjunctive intermittent pneumatic calf compression. J Bone Joint Surg [Br] 2008;90-B:562–569.
25. Dorr LD, Gendelman V, Maheshwari AV. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg [Am] 2007;89-A:2469–2473.
26. Dorr LD, Raya J, Long WT, Boutary M, Sirinanni LE. Multimodal analgesia without parenteral narcotics for total knee arthroplasty. J Arthroplasty 2008;23:502–508.
27. Huang R, Buckley PS, Scott B, Parvizi J, Pantil JJ. Administration of aspirin as a prophylaxis agent against venous thromboembolism results in lower incidence of periprosthetic joint infection. J Arthroplasty 2015;30(9 Suppl):39–41.
28. Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molec- 
ular-weight heparin on venous thromboembolism after knee replacement: a non-
randomised comparison using National Joint Registry Data. J Bone Joint Surg [Br] 
2012;94-B:914–918.

29. Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of 
aspirin and low-molecular-weight heparin on venous thromboembolism after hip 
replacement: a non-randomised comparison from information in the National 
Joint Registry. J Bone Joint Surg [Br] 2011;93-B:1465–1470.

30. Kariythean G, Eikeboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) 
have a role in the prevention of venous thromboembolism? Br J Haematol 
2000;146:142–149.

31. Lachiewicz PF, Klein JA, Holleman JB Jr, Kelley S. Pneumatic compression or 
aspirin prophylaxis against thromboembolism in total hip arthroplasty. J South Orthop 
Assoc 1996;5:272–280.

32. Lachiewicz PF, Soileau ES. Mechanical calf compression and aspirin prophylaxis 
for total knee arthroplasty. Clin Orthop Relat Res 2007;464:61–64.

33. McCordel BR, Lachiwiecz PF, Jones K. Aspirin prophylaxis and surveillance of 
vascular embolism and deep vein thrombosis in total hip arthroplasty. J Arthro-
plasty 1990;5:181–185.

34. Reitman RD, Emerson RH, Higgins LL, Tarbox TR. Does acetyl salicylic acid 
prophylaxis against thromboembolism in total hip arthroplasty. J Arthroplasty 
2003;18:161–168.

35. Stulberg BN, Dorr LD, Ranawat CS, Schneider R. A multimodality regimen for 
34. Reitman RD, Emerson RH, Higgins LL, Tarbox TR. Aspirin prophylaxis and surveillance of 
venous thromboembolism is rare in the first 3 months after total joint arthroplasty. 
J Bone Joint Surg [Am] 2010;92-B:119–123.

36. Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for 
thromboprophylaxis in modern elective total hip and knee arthroplasty. J Bone Jt 
2012;90-B:1056–1061.

37. Raphael IJ, McKenzie JC, Zmistowski B, et al. Prevention of venous thromboembolism after 
total hip arthroplasty: a randomized controlled study. J Arthroplasty 
2010;25:660–664.

38. Van V, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee 
arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2016;31:2688– 
2616.

39. Ogonda L, Hill J, Doran E, et al. Aspirin for thromboprophylaxis after primary lower 
limb arthroplasty: early thromboembolic events and 90 day mortality in 11,459 
patients. Bone Joint J 2016;88-B:341–348.

40. Feldstein MJ, Lov SL, Chen AF, Woodward LA, Hozack WJ. A comparison of 
two dosing regimens of asa following total hip and knee arthroplasties. J Arthro-
plasty 2015;30:442–450.

41. Goyal N, Chen AF, Padgett SE, et al. Pre-emptive injection of peri-articular-multi-
lar compression or 
Aspirin prophylaxis against thromboembolism in total hip arthroplasty. J South Orthop 
Assoc 1996;5:272–280.

42. Feldstein MJ, Low SL, Chen AF, Woodward LA, Hozack WJ. A comparison of 
thromboembolism following total hip arthroplasty. An incidence study. Clin Orthop 
Relat Res 1992;189:119–123.

43. Parvizi J, Huang R, Restrepo C, et al. A comparison of 
42. Feldstein MJ, Low SL, Chen AF, Woodward LA, Hozack WJ. A comparison of 
Mobile compression 
Aspirin prophylaxis against thromboembolism in total hip arthroplasty. J Arthroplasty 
2003;18:161–168.

44. Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molec-
ular-weight heparin on venous thromboembolism after knee replacement: a non-
randomised comparison using National Joint Registry Data. J Bone Joint Surg [Br] 
2012;94-B:914–918.

45. Reitman RD, Emerson RH, Higgins LL, Tarbox TR. Aspirin prophylaxis against 
thromboembolism in total hip arthroplasty. J Arthroplasty 
2003;18:161–168.

46. Stulberg BN, Dorr LD, Ranawat CS, Schneider R. A multimodality regimen for 
thromboembolism following total hip arthroplasty. An incidence study. Clin Orthop 
Relat Res 1992;189:119–123.

47. Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for 
thromboprophylaxis in modern elective total hip and knee arthroplasty. J Bone Jt 
2012;90-B:1056–1061.

48. Raphael LJ, McKenzie JC, Zmistowski B, et al. Pulmonary embolism after total 
joint arthroplasty: cost and effectiveness of four treatment modalities. J Arthro-
plasty 2014;29:933–937.

49. Dalury D, Lonner J, Parvizi J. Prevention of venous thromboembolism after 
total joint arthroplasty: aspirin is enough for most patients. Am J Orthop (Belle 
Meud NJ) 2014;55:60.

50. Nam D, Nunley RM, Johnson SR, Keeney JA, Barrack RL. Mobile compression 
devices and aspirin for VTE prophylaxis following simultaneous bilateral total 
knee arthroplasty. J Arthroplasty 2015;30:442–450.

51. An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee 
arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2016;31:2688– 
2616.

52. Honda US, Mandelblatt AE, Callanan MA, MacDonald JH, King PJ. Incidence, 
risk factors, and costs for hospital returns after total joint arthroplasty. J Arthro-
plasty 2017;32:381–385.

53. Parvizi J, Ghanem E, Joshi A, et al. Does “excessive” anticoagulation predispose 
to periprosthetic infection? J Arthroplasty 2007;22(Suppl 2):24–28.

54. Sachs RA, Smith JH, Kuney M, Paxton L. Does anticoagulation do more harm than 
good? A comparison of patients treated without prophylaxis and patients treated 
with low-dose warfarin after total knee arthroplasty. J Arthroplasty 
2003;18:389–395.

55. Vasso M, Schiavone Panni A, De Martino I, Gasparini G. Prosthetic knee injec-
tion by resistant bacteria: the worst-case scenario. Knee Surg Sports Trauma-
tol Arthrosc 2016;24:3140–3146.

56. Zmistowski BM, Marquie J, Patel R, Chen AF. Recurrent periprosthetic joint 
infection after irrigation and debridement with component retention is most often due 
to identical organisms. J Arthroplasty 2016;31(B Suppl):148–151.

57. No authors listed. National Clinical Guideline Centre – Acute and Chronic Condi-
tions. Venous thromboembolism: reducing the risk of venous thromboembolism (deep 
vein thrombosis and pulmonary embolism) in patients admitted to hospital. 2010. 
https://www.nice.org.uk/guidance/CG92/evidence/full-guideline-pdf-243920125 
(date last accessed 13 September 2017).

58. No authors listed. SIGN. Prevention and management of venous thromboembolism: 
a national clinical guideline. 2014. http://www.sign.ac.uk/assets/sign122.pdf (date 
last accessed 25 July 2017).

59. Rosen LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann 
Med Surg 1953;2:95.

60. Patrino C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of 
Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 
2008;133(Suppl):1995–2335.

61. Patrino C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009;7(Suppl 
1):258–261.

62. Roth DJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspi-
rin. Proc Natl Acad Sci U S A 1975;72:3073–3076.

63. Undas A, Brummel-Ziedins K, Mana KG. Why does aspirin decrease the risk of 
venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic 
acid. J Thromb Haemost 2014;12:1778–1787.

64. Foster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. 
Circulation 2011;123:768–778.
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S–264S.

Hamer JD, Malone PC, Silver IA. Antiplatelet drugs: platelet-activating factors and the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Anal Biochem 1999;272:54–70.

Valsamis S, Ruf W, Leikauf GS, et al. Immunomodulatory drugs increase endothelial tissue factor expression in vitro. Thromb Res 2011;127:264–271.

Svensson J, Bergman AC, Adamson U, et al. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometry and isotope labeling study. Biochem Biophys Res Commun 2012;421:335–342.

Undas A, BrummeI K, Musial J, Mann KG, Szczeklik A. P(II(2)a) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2686–2692.

Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1777–1783.

Brinkmann V, Reichard U, Goossen C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532–1535.

von Bürh UL, Stark K, Steinhardt A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819–835.

Fuchs TA, Brill A, Derschmidt D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880–15895.

Lupponi MJ, Carestia A, Landoni V, et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 2013;345:434–437.

Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959–1967.

Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979–1987.

Parviz J, Zazzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty 2008;23(7 Suppl 2):1–5.

Jennings JD, Harris WH, Sarmiento A. A clinical evaluation of aspirin prophylaxis of thromboembolic disease after total hip arthroplasty. J Bone Joint Surg [Am] 1976;58-A:926–929.

Gillette B, Desimone LJ, Trousdale RT, Pagnano MW, Sierra R. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 2013;471:150–154.

Sarmiento A, Goswami AD. Thrombolytic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg [Am] 1999;81-A:339–346.

Khatod M, Inacio MC, Bini SA, Paxton EW. Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice? J Arthroplasty 2012;27:167–172.

Antithrombotic Trialsists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–78.

de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1.

Westrich GH, Bottner F, Windsor RE, et al. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thrombolytic disease prophylaxis in total knee arthroplasty. J Arthroplasty 2006;21(6 Suppl 2):139–143.

Gesell MW, Gonzalez Della Valle A, Bartolome Garcia S, et al. Safety and efficacy of multimodal thromboprophylaxis following total knee arthroplasty: a comparative study of preferential aspirin vs. routine coumadin chemoprophylaxis. J Arthroplasty 2013;28:575–579.

Kulshrestha V, Kumar S. DVT prophylaxis after TKR: routine anticoagulation vs risk screening approach - a randomized study. J Arthroplasty 2013;28:1868–1873.

Ryan MG, Westrich GH, Potter HG, et al. Effect of mechanical compression on the prevalence of proximal deep vein thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg [Am] 2002;84-A:1986–2004.

Sarmiento A, Goswami A. Thrombolytic disease prophylaxis in total hip arthroplasty. Clin Orthop Relat Res 2005;438:138–143.

The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827–830.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparison of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2009;360:803–810.

van Ginj A, Algra A, Kappelle J, et al. A comparison of two doses of aspirin (30 mg vs. 263 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–1266.
129. Harris WH, Ahanasoulis CA, Waltsman AC, Salzman EW. High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. J Bone Joint Surg [Am] 1982;64-A:63–66.

130. Paiement GD, Schutzer SF, Wessinger SJ, Harris WH. Influence of prophylaxis on proximal venous thrombus formation after total hip arthroplasty. J Arthroplasty 1982;7:471–474.

131. Geller Y, Tavor H, Oron A, et al. Deep vein thrombosis prevention in joint arthroplasty: continued enhanced circulation therapy vs low molecular weight heparin. J Arthroplasty 2006;21:206–214.

132. Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg [Am] 2003;85-A:1256–1262.

133. Alfaro MJ, Páramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost 1988;56:53–56.

134. Beuhler KO, D’Lima DD, Colwell CW Jr, Otis SM, Walker RH. Venous thromboembolic disease after hybrid hip arthroplasty with negative duplex screening. Clin Orthop Relat Res 1999;361:168–177.

135. Guyer RD, Booth RE Jr, Rothman RH. The detection and prevention of pulmonary embolism in total hip replacement. A study comparing aspirin and low-dose warfarin. J Bone Joint Surg [Am] 1982;64-A:1040–1044.

136. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMU 2008;336:195–198.

137. Parvizi J, Huang R, Raphael JI, et al. Timing of Symptomatic Pulmonary Embolism with Warfarin Following Arthroplasty. J Arthroplasty 2015;30:1050–1055.

138. Bayley E, Brown S, Bhamber NS, Howard PW. Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study. Bone Joint J 2016;88-B:585–588.

139. Hunt LP, Ben-Shlomo Y, Clark EM, et al. The Frank Stinchfield Award. Lancet 2011;378:1760–1762.

140. Hunt LP, Ben-Shlomo Y, Clark EM, et al. The detection and prevention of pulmonary embolism in total hip replacement: an observational study. Lancet 2014;384:1429–1436.

141. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg [Br] 2005;87-B:1675–1680.

142. Blom A, Pattison G, Whitehouse S, Taylor A, Bannister G. Early death following primary total hip arthroplasty: 1,727 procedures with mechanical thromboembolic prophylaxis. Acta Orthop 2008;79 347–350.

143. Parvizi J, Holiday AD, Ereh MH, Lewallen DG. The Frank Stinchfield Award. Sudden death during primary hip arthroplasty. Clin Orthop Relat Res 1998;349:38–48.

144. Devereaux PJ, Xavier D, Pogue J, et al. POISE (PeriOperative ISchemic Evalua- tion) Investigators. Characteristic and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523–529.

145. Savonitto S, Caracciolo M, Cattaneo M, DE Servi S. POISE (PeriOperative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523–529.

146. Mostafavi Tabatabaea B, Rasouli MR, Maltenfort MG, Parvizi J. Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin. J Arthroplasty 2003;18:190–195.

147. Jameson SS, Baker PN, Deehan DJ, Port A, Reed MR. Evidence-base for aspirin versus placebo in total joint replacement. Bone Joint Res 2014;3:145–148.

148. Meek IL, Vonkeman HE, Kasemier J, Movic KL, van de Laar MA. Interference of NSAIDs with the thromboxane inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 2013;69:385–391.

149. Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010;39:294–312.

150. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295–1301.

151. Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011;63:850–859.

152. Weil J, Colon-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;316:623–630.

153. Ivanamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastrointestinal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 2013;19:1873–1882.

154. Croy B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1998;117:17–25.

155. Guo W, Lu W, Xu Y, et al. Relationship between adverse gastric reactions and the timing of enteric-coated aspirin administration. Clin Drug Invest 2017;37:187–193.

156. Takahashi S, Mizuno O, Sakaguchi T, Yamada T, Inuyama E. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. Adv Ther 2014;31:118–129.

157. Feldstein MJ, Low SL, Chen AF, Woodward LA, Hozack WJ. A comparison of two dosing regimes of ASA following total hip and knee arthroplasties. J Arthroplasty 2013;28:851–855.

158. Snyder MA, Symson AN, Scheuerman CM, Gregg JL, Hussain LR. Efficacy in delaying vein thrombosis prevention with extended mechanical compression device ther- apy and prophylactic aspirin following total knee arthroplasty in a randomized control trial. J Arthroplasty 2017;32:1478–1482.

159. Lee YK, Chung CY, Koo KH, et al. Conflict of interest in the assessment of thromboembolic disease following total joint arthroplasty: a systematic review. J Bone Joint Surg [Am] 2012;94-A:27–33.

160. No authors listed. Charity Commission for England and Wales. Accounts and annual return for Thames UK 2016. http://apps.charitycommission.gov.uk/Showcharity/ RegisterOfCharities/CharityWithoutPartB.aspx?RegisteredCharityNum- ber=1090548&SubsidiaryNumber=0 (date last accessed 25 July 2017).

161. No authors listed. Insight Consulting Group. Trusted by/ (date last accessed 25 July 2017).

162. No authors listed. House of Commons. Guide to the Rules on All-Party Groups. 2010. http://www.parliament.uk/documents/pdfs/all-party-groups/guide-to-the-rules-on- all-party-groups.pdf (date last accessed 13 September 2017).

163. No authors listed. British Hip Society. Newsletter July 2011. https://www.british-hipsociety.com/uploaded/Newsletter%20July%202011.pdf (date last accessed 25 July 2017).

164. Donohoe CL, Sayana MK, Thakral R, Niall DM. Aspirin for lower limb arthro- plasty thromboprophylaxis: review of international guidelines. Ir J Med Sci 2011;180:632–637.

165. No authors listed. Clinical experts or methodologists to write clinical guidelines? Lancet 2009;374:273–275.

166. No authors listed. The National Academies of Sciences, Engineering, and Medicine. Our Study Process. 2017. http://nationalacademies.org/studyprocess/index.html (date last accessed 25 July 2017).

167. No authors listed. American Association of Orthopaedic Surgeons. Clinical Practice Guidelines. 2017. http://www.aaos.org/guidelines/?ssopc=1 (date last accessed 25 July 2017).
178. No authors listed. House of Commons, Guide for witnesses giving written or oral evidence to a House of Commons select committee. 2016. https://www.parliament.uk/documents/commons-committees/witnessguide.pdf (date last accessed 25 July 2017).

179. Allen D, Sale G. Lower limb joint replacement in patients with a history of venous thromboembolism. Bone Joint J 2014;96-B:1515–1519.

180. Bohl DD, Maltenfort MG, Huang R, et al. Development and validation of a risk stratification system for pulmonary embolism after elective primary total joint arthroplasty. J Arthroplasty 2016;31(9 Suppl):187–191.

181. Nam D, Nunley RM, Johnson SR, et al. Thromboembolism prophylaxis in hip arthroplasty: routine and high risk patients. J Arthroplasty 2015;30:2299–2303.

182. Nam D, Nunley RM, Johnson SR, et al. The effectiveness of a risk stratification protocol for thromboembolism prophylaxis after hip and knee arthroplasty. J Arthroplasty 2016;31:1299–1306.

183. Parvizi J, Huang R, Rezaaoor M, Bagheri B, Maltenfort MG. Individualized risk model for venous thromboembolism after total joint arthroplasty. J Arthroplasty 2016;31(9 Suppl):180–186.

184. Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care 2014;18:549.

185. No authors listed. Centers for Disease Control and Prevention. Genetic Tests for Idiopathic Venous Thromboembolism: EGAPP™ Recommendation. 2011. https://www.cdc.gov/genomics/egapp/recommend/fvl.htm (date last accessed 25 July 2017).